Adicet Bio, Inc. (ACET)

NASDAQ: ACET · IEX Real-Time Price · USD
11.53
-0.42 (-3.51%)
Jan 27, 2022 4:00 PM EST - Market closed
Market Cap451.32M
Revenue (ttm)9.67M
Net Income (ttm)-55.14M
Shares Out39.14M
EPS (ttm)-2.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume117,172
Open12.12
Previous Close11.95
Day's Range11.45 - 12.52
52-Week Range6.25 - 18.49
Betan/a
AnalystsStrong Buy
Price Target30.86 (+167.6%)
Earnings Daten/a

About ACET

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company a...

IndustryHealth Care Providers & Services
Founded1947
CEOChen Schor
Employees81
Stock ExchangeNASDAQ
Ticker SymbolACET
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for Adicet Bio stock is "Strong Buy." The 12-month stock price forecast is 30.86, which is an increase of 167.65% from the latest price.

Price Target
$30.86
(167.65% upside)
Analyst Consensus: Strong Buy

News

3 Biotech Stocks That Could Double in 2022

They're risky. But with the high risk comes the potential for high rewards.

Other symbols:CCXINRXP
3 weeks ago - The Motley Fool

Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters...

MENLO PARK, Calif. and BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapie...

1 month ago - GlobeNewsWire

Adicet Bio Raises $87M Via Equity To Fund Development Of Non-Hodgkin's Lymphoma Candidate

Adicet Bio Inc (NASDAQ: ACET) priced an underwritten public offering of 6.25 million shares at $14.00 per share, raising gross proceeds of $87.5 million. The offer price represents a discount of almost ...

1 month ago - Benzinga

Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock

MENLO PARK, Calif. and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapie...

1 month ago - GlobeNewsWire

Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock

MENLO PARK, Calif. and BOSTON, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapie...

1 month ago - GlobeNewsWire

Why Adicet Bio Stock Is Skyrocketing Today

The company reported positive interim results from a phase 1 study.

1 month ago - The Motley Fool

Adicet Stock Rallies After Early Responses For Off-The-Shelf Drug In B-cell Non-Hodgkin's Lymphoma

Adicet Bio Inc (NASDAQ: ACET) has announced positive interim data from its dose-escalation Phase 1 study evaluating ADI-001 for B-cell Non-Hodgkin's Lymphoma.  Adicet's AD-001 is an off-the-shelf cell t...

1 month ago - Benzinga

Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Inve...

MENLO PARK, Calif. and BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR T cell ther...

1 month ago - GlobeNewsWire

Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin's Lymphoma

ADI-001 is the first ever allogeneic, off-the-shelf, gamma delta CAR T cell therapy to report clinical data

1 month ago - GlobeNewsWire

Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors

MENLO PARK, Calif. and BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...

2 months ago - GlobeNewsWire

Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Ann...

Adicet's allogeneic gamma delta CAR-T cell therapy candidate is designed to combine CAR targeting and cell intrinsic IL-15 armoring with the innate and adaptive immune effector functions of the Company'...

2 months ago - GlobeNewsWire

Adicet Bio, Inc. (ACET) Reports Q3 Loss, Lags Revenue Estimates

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -15.79% and -26.26%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Adicet Reports Third Quarter 2021 Financial Results and Provides Business Updates

MENLO PARK, Calif. and BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...

2 months ago - GlobeNewsWire

Adicet Bio to Participate in Stifel 2021 Virtual Healthcare Conference

MENLO PARK, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cance...

2 months ago - GlobeNewsWire

Adicet Announces Trials in Progress Poster Presentation for ADI-001 at 2021 ASH Annual Meeting

MENLO PARK, Calif. and BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...

2 months ago - GlobeNewsWire

CDR-Life Announces Expansion of Scientific Advisory Board

Two renowned experts join to advise CDR-Life as the company advances pipeline of novel cancer therapeutic candidates Two renowned experts join to advise CDR-Life as the company advances pipeline of nove...

3 months ago - GlobeNewsWire

Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific Officer

MENLO PARK, Calif. and BOSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...

3 months ago - GlobeNewsWire

Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual Meeting

MENLO PARK, Calif. and BOSTON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...

3 months ago - GlobeNewsWire

Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif. & MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience and Adicet Bio collaboration to accelerate the discovery of gamma delta T cell therapies against five undiscl...

Other symbols:TWST
4 months ago - Business Wire

Adicet Bio to Participate in Upcoming Investor Conferences

MENLO PARK, Calif. and BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer a...

4 months ago - GlobeNewsWire

Adicet Bio, Inc. (ACET) Reports Q2 Loss, Tops Revenue Estimates

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 33.33% and 6.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates

On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by the end of 2021 On track to report top-line interim data from ADI-001 Phase 1 study in Non-Hodgkin'...

5 months ago - GlobeNewsWire

Adicet Bio Announces Formation of Scientific Advisory Board

MENLO PARK, Calif and BOSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and...

6 months ago - GlobeNewsWire

Adicet Bio Added to the Russell 2000® Index

MENLO PARK, Calif. and BOSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer an...

6 months ago - GlobeNewsWire

Moving Average Crossover Alert: Adicet Bio (ACET)

Adicet Bio (ACET) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

7 months ago - Zacks Investment Research